The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research. 

Michael Reardon, MD, co-principal investigator of the ACURATE IDE trial, discussed updated data on what may have impacted that study's findings.

In some cases, the method even helps to home in on sentinel nodes that may not have been identified during prior biopsy.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Towana Looney, 53, is recovering well but still under observation by the NYU Langone doctors who performed the groundbreaking procedure. 

Use of the new tracer could improve outcomes by enabling providers to adjust treatment regimens much earlier than they have been able to previously. 

Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 44% if caught early, dropping down to 3% if it metastasizes. This is largely due to its ability to elude detection.

The CDC estimates that over 6 million people in the U.S. struggle with OUD, and prior research has indicated that only 20% receive treatment for the disorder.